Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting CD43 optimizes cancer immunotherapy through reinvigorating anti-tumor immune response in colorectal cancer

ABSTRACT: Targeting CD43 optimizes cancer immunotherapy through reinvigorating anti-tumor immune response in colorectal cancer

PROVIDER: PRJNA928680 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23252700_1.fastq.gz	Fastqsanger.gz
	SRR23252700_2.fastq.gz	Fastqsanger.gz
	SRR23252701_1.fastq.gz	Fastqsanger.gz
	SRR23252701_2.fastq.gz	Fastqsanger.gz
	SRR23252693_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Targeting CD43 optimizes cancer immunotherapy through reinvigorating anti-tumor immune response in colorectal cancer

Project description:We report a novel immune molecule, CD43, that can regulate the tumor immune microenvironment (TIME) and serves as a promising target for CRC immunotherapy. The correlation of CD43 expression with CRC patient prognosis was revealed by public data analysis. CD43 KO CRC cell lines were generated by CRISPR-CAS9 technology, and a syngenetic murine CRC model was established to investigate the in vivo function of CD43.To elucidate the TIME more precisely, tumors were harvested at Day 21 postinoculation in vivo, and single-cell suspensions of tumor tissues were generated for transcriptome sequencing.

2023-05-01 | GSE223856 | GEO

Human lung cancer cell line A549 +/- CD43 knockdown

Project description:The human lung cancer cell line A549 with high CD43 expression was stably trasfected with a vector expressing a non-functional shRNA or 3 of these same vectors each expressing a different shRNA targeting human CD43 mRNA. The transcriptomes of these two daughter lines were then compared by differential microarray analysis. The generation and functional characteristics of these two daughter cell lines are described by Fu et al., in the International Journal of Cancer, volume 132, pages 1761-1770, published in 2013.

2024-07-01 | GSE180769 | GEO

Triple-negative breast cancer cell line MDA-MB-231 +/- CD43 knockdown

Project description:The triple-negative breast cancer cell line MDA-MB-231 with high CD43 expression was stably transfected with a vector expressing a non-functional shRNA or 4 of these same vectors each expressing a different shRNA targeting human CD43 mRNA. The transcriptomes of these two daughter lines were then compared by differential microarray analysis.

2021-05-04 | GSE173757 | GEO

mRNA profiles of CD43++c-kit+, CD43+c-kit- and CD43-c-Kit- AML1-ETO9a murine leukemic bone marrow cells

Project description:We discovered a spontaneous differentiation path characterized by CD43 and c-Kit in the AE9a murine model, where the leukemia-initiating potential is lost while leukemic cells display features of erythroid maturation. Therefore, we sorted out CD43++c-Kit+, CD43+c-Kit- and CD43-c-Kit- AE9a leukemic cells for RNA-sequencing analyses to determine the underlying transcriptome.

2022-10-03 | GSE186040 | GEO

Targeting metabolism to improve immunotherapy in GSNOR-deficient colorectal cancer

Project description:Targeting metabolism to improve immunotherapy in GSNOR-deficient colorectal cancer

| PRJNA1099593 | ENA

Targeting metabolism to improve immunotherapy in GSNOR-deficient colorectal cancer

Project description:Targeting metabolism to improve immunotherapy in GSNOR-deficient colorectal cancer

| PRJEB74194 | ENA

Targeting metabolism to improve immunotherapy in GSNOR-deficient colorectal cancer

Project description:Targeting metabolism to improve immunotherapy in GSNOR-deficient colorectal cancer

| PRJEB74195 | ENA

Human lung cancer cell line A549 +/- CD43 knockdown

Project description:Human lung cancer cell line A549 +/- CD43 knockdown

| PRJNA749458 | ENA

RNA-seq of effector (CD43+) CD8+ T cells, CD45+ hematopoietic cells and CD45- tumor/stromal cells from mice bearing bilateral AT-3 tumors following radio-immunotherapy of which one tumor was irradiated

Project description:Radiotherapy (RT) destroys tumor cells, which may lead to release of antigens and immune-activating signals. In this way, RT may act as an in situ vaccine and kick-start a T-cell response against the tumor. Immunotherapy enhances tumor-specific T-cell responses. Combination of radiotherapy and immunotherapy (radio-immunotherapy (RIT)) can therefore be expected to synergize in inducing and sustaining systemic anti-tumor T-cell responses. However, in the clinic, systemic combined responses between radiotherapy and immunotherapy are rarely observed, as the effect of RIT combinations on ‘abscopal’ tumors outside the radiotherapy field are not (yet) greater than the effect of immunotherapy alone. In order to define potential bottlenecks in the tumor micro-environment that impede CD8 T cell activity, we harvested irradiated and non-irradiated tumors from the same mice that were treated with RIT (10 Gy RT, anti-CD137 and anti-PD1). From these tumors, effector (CD43+) CD8 T cells, ‘other’ hematopoietic (CD45+) cells and tumor/stromal (CD45-) were sorted and RNA sequencing was performed to identify differences between these cell populations in the irradiated and non-irradiated tumors that could explain the lack of T cell activity in the non-irradiated tumor.

2019-02-12 | E-MTAB-6914 | biostudies-arrayexpress

Clostridioides difficile CD43

Project description:Clostridioides difficile CD43 Genome sequencing and assembly

| PRJNA85705 | ENA